Inspire Medical Systems, Inc. (NYSE:INSP) Receives $233.58 Average PT from Analysts

Inspire Medical Systems, Inc. (NYSE:INSP) has earned a consensus recommendation of “Moderate Buy” from the twelve ratings firms that are covering the stock, Marketbeat.com reports. Three investment analysts have rated the stock with a hold recommendation and nine have assigned a buy recommendation to the company. The average 1-year target price among brokers that have issued ratings on the stock in the last year is $233.58.

INSP has been the topic of several recent analyst reports. Piper Sandler reiterated an “overweight” rating and set a $260.00 price target (up from $255.00) on shares of Inspire Medical Systems in a report on Tuesday, November 5th. Bank of America upgraded shares of Inspire Medical Systems from a “neutral” rating to a “buy” rating and upped their target price for the company from $220.00 to $255.00 in a research note on Wednesday, November 20th. Truist Financial restated a “buy” rating and issued a $240.00 price target (up from $217.00) on shares of Inspire Medical Systems in a research report on Monday, September 30th. Robert W. Baird upped their price objective on shares of Inspire Medical Systems from $240.00 to $252.00 and gave the company an “outperform” rating in a research report on Tuesday, November 5th. Finally, Royal Bank of Canada reissued an “outperform” rating and set a $260.00 target price on shares of Inspire Medical Systems in a research report on Tuesday, November 5th.

Institutional Trading of Inspire Medical Systems

Institutional investors have recently bought and sold shares of the stock. True Wealth Design LLC bought a new position in shares of Inspire Medical Systems during the third quarter valued at $30,000. Farther Finance Advisors LLC lifted its holdings in Inspire Medical Systems by 1,158.3% during the 3rd quarter. Farther Finance Advisors LLC now owns 151 shares of the company’s stock valued at $32,000 after purchasing an additional 139 shares during the last quarter. GAMMA Investing LLC boosted its position in Inspire Medical Systems by 559.3% in the third quarter. GAMMA Investing LLC now owns 178 shares of the company’s stock valued at $38,000 after buying an additional 151 shares in the last quarter. SouthState Corp bought a new stake in Inspire Medical Systems during the second quarter worth about $27,000. Finally, Signaturefd LLC increased its holdings in shares of Inspire Medical Systems by 45.9% during the third quarter. Signaturefd LLC now owns 270 shares of the company’s stock worth $57,000 after buying an additional 85 shares in the last quarter. Institutional investors and hedge funds own 94.91% of the company’s stock.

Inspire Medical Systems Trading Down 0.7 %

NYSE:INSP opened at $186.29 on Friday. The firm has a market capitalization of $5.58 billion, a PE ratio of 174.10 and a beta of 1.31. Inspire Medical Systems has a 1 year low of $123.00 and a 1 year high of $257.40. The firm’s fifty day simple moving average is $191.90 and its 200 day simple moving average is $180.30.

Inspire Medical Systems (NYSE:INSP) last issued its quarterly earnings results on Monday, November 4th. The company reported $0.60 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.06 by $0.54. Inspire Medical Systems had a return on equity of 5.30% and a net margin of 4.37%. The company had revenue of $203.20 million for the quarter, compared to the consensus estimate of $197.59 million. During the same period last year, the business posted ($0.29) earnings per share. The firm’s revenue was up 32.6% compared to the same quarter last year. As a group, analysts anticipate that Inspire Medical Systems will post 1.33 EPS for the current fiscal year.

Inspire Medical Systems Company Profile

Inspire Medical Systems, Inc, a medical technology company, focuses on the development and commercialization of minimally invasive solutions for patients with obstructive sleep apnea (OSA) in the United States and internationally. The company offers Inspire system, a neurostimulation technology that provides a safe and effective treatment for moderate to severe OSA.